Feb 7th 2023 - Mar 21st 2023
Data tells me no safety issues, with a possible la... See more
Then they dropped the “good” totally “not disappoi... See more
Feb 7th 2023 - Mar 21st 2023
We are excited about the data and plan to submit t... See more
$AVXL Australia trial data meets the gold standard.
The Motley Fool Stock Advisor has a track record that speaks for itself, with average recommendations that have returned over 542%*. Act now so you can start investing smarter, not harder.
*As of October 2023$79 is an introductory price for new members only. 60% discount based on the current list price of Stock Advisor of $199/year. Membership will renew annually at the then current list price.Feb 7th 2023 - Mar 21st 2023
$BCRX European stocks rose on Friday as investor... See more
#1 Suddenly alot of positive accounts appear, prom... See more
Data tells me no safety issues, with a possible large therapeutic window.
Then they dropped the “good” totally “not disappointing” data that Remi was so “Thrilled” about.
This will go beyond parabolic on good data … literally no shares out there unless they offer new ones … $MDGL $VKTX $SLS $SAVA
SAVA data gets analyzed by multiple different labs and shows its cognition improvement in mild AD cases, safe and well-tolerated
$SAVA I love not being able to hold $28 off data that will keep it pinned here until 2024.
but the data to date would predict continued efficacy that will be nigh on impossible to ignore.
Data teasing is very positive. 🚀
$SAVA Institutional buying says data is good!! !
I’ll keep buying until data comes out…
Excited for the next data unveiling….bring it on!
We are excited about the data and plan to submit the data for publication and peer reviewed medical journal in the near term.
$AVXL Australia trial data meets the gold standard.
$AVXL - Alz Topline Data was solid ..
Efficacy is likey overwhelming after seeing 👀 data details!
$AVXL I am extremely bullish on the data .. the FDA can ask any sorts of questions
I'm looking forward to seeing the long term AD data on ANVS and have the feeling it's going to end up being the best in class AD treatment as well.
Now DATA met expectations.
Also clint said every time Blarcamesine data comes back it looks better and better. .
Anavex has significant 4 years of ph2/3 safety data with safety back to 2013 for Blarcamesine .. anavex has full 3 endpoint trial and a placebo .. it's obvious Anavex wins!!
So I think the data so far was encouraging,
$BCRX European stocks rose on Friday as investors took an optimistic view of a week of data releases that showed economies in Europe and the US were more robust than expected.
#1 Suddenly alot of positive accounts appear, promoting the company has solid data, solid sales
$BCRX Have strong feeling once 10013 data is out we are going places.
P1 data is nice ,
The data looks good.
$BCRX This preliminary data on BCX10013 is pretty impressive.
$BCRX Good 10013 data.
10013 data looks good,
$BCRX great 10013 data and 320+ projected rev
but it also seems like the good choice to do so seeing iptacopan data.
